Dresden
Universitätsklinikum Dresden
The combinatorial use of therapeutic monoclonal antibodies Cetuximab and Trastuzumab with a TIGIT-blocking antibody enhances cytotoxicity of NK cells against primary glioblastoma cells expressing EGFR and ERBB2
The combinatorial use of therapeutic monoclonal antibodies Cetuximab and Trastuzumab with a TIGIT-blocking antibody enhances cytotoxicity of NK cells against primary glioblastoma cells expressing EGFR and ERBB2
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.